Study the Relationship of MDCT Staging in Disease Extent with the Systemic Sclerosis Disease Parameters

Reumatol Clin (Engl Ed). 2022 Dec;18(10):597-602. doi: 10.1016/j.reumae.2021.04.017.


Background and objectives: The highest incidence of death in systemic sclerosis due to pulmonary disease raises the need for early detection and treatment. The study aim is the assessment of interstitial pulmonary disease by Multi Detector High Resolution CT (MDCT) and finds its relationship with the other disease parameters and the Pulmonary Function tests (PFT).

Patients and methods: A prospective cross-sectional study was performed in Assiut University Hospitals from May 2018 to January 2020 and included 62 consecutive SSc female patients. Demographic, clinical, Laboratory, PFT and MDCT assessment were conducted for all participants.

Results: The coarseness of fibrosis was 8.32 (range 0.0-17), the average proportion of ground-glass opacification was 28.3% (range, 0.0%-75%). Honey-comb pattern was seen in (52.5%). Mean Extent of disease was 46.25±3.7 (range 5-81). Restrictive deficit found in 42 patients. Significant relation was found between the extent of disease and the percentage predicted FVC (r=0.373, p 0.018) and FEV1/FVC (r=0.593, p 0.000) and coarseness of fibrosis and proportion of ground glass opacification correlated inversely with VC (r=-0.385, p=0.014, r=-0.376, p=0.017 respectively), Rayanud's phenomena, modified Rodnan Skin Score and Medsger's general are positively correlated with MDCT disease extent.

Conclusion: Scoring of systemic sclerosis (SSc) related interstitial lung disease (SSc-ILD) could be applicable as one of the important tools for disease assessment.

Keywords: Esclerosis sistémica; MDCT; PFP; PFTs; Puesta en escena; Staging; Systemic sclerosis; TCMD.

MeSH terms

  • Cross-Sectional Studies
  • Female
  • Fibrosis
  • Humans
  • Lung Diseases, Interstitial* / diagnostic imaging
  • Lung Diseases, Interstitial* / etiology
  • Prospective Studies
  • Scleroderma, Localized* / complications
  • Scleroderma, Systemic* / complications
  • Scleroderma, Systemic* / diagnostic imaging
  • Tomography, X-Ray Computed / adverse effects